Neurological Manifestations in Primary Sjögren’s Syndrome: A Comparative Review of Inflammatory Mechanisms
Neuroinflammatory Mechanisms in Sjögren’s Syndrome
DOI:
https://doi.org/10.22317/jcms.v11i2.1781Keywords:
Primary Sjögren's syndrome, Central Nervous system, Neuroinflammatory Diseases, PathologyAbstract
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disorder marked by chronic inflammation, with neurological involvement often overlooked. This review highlights the inflammation-driven mechanisms underlying both peripheral and central nervous system (PNS, CNS) manifestations of pSS. PNS complications, particularly axonal sensorimotor and pure sensory neuropathies, are more common than CNS involvement. CNS abnormalities include diffuse white matter lesions and hippocampal atrophy. Immune dysregulation plays a central role, with emerging evidence implicating NLRP3 inflammasome activation and vasculitic processes. Aberrant B-cell activity may lead to pathogenic autoantibody production and direct neural injury. Infiltration of T- and B-cells into neural tissues, facilitated by astrocyte-mediated disruption of the blood-brain barrier, promotes cytokine-driven neuroinflammation. These processes contribute to cognitive, sensory, and motor dysfunction in pSS. Although conventional and biological therapies show promise, robust clinical trials are lacking. Understanding the immunopathogenesis of pSS may pave the way for targeted interventions. This review synthesizes current findings on neuroinflammatory mechanisms in pSS and their clinical implications.
References
Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clinical immunology (Orlando, Fla). 2019;203:81-121.
Tian Y, Yang H, Liu N, Li Y, Chen J. Advances in pathogenesis of Sjögren’s syndrome. Journal of immunology research. 2021;2021(1):5928232.
Barrio-Cortes J, López-Rodríguez JA, Gómez-Gascón T, Rayo-Gómez Á, del Cura-González I, Domínguez-Berjón F, et al. Prevalence and comorbidities of Sjogren's syndrome patients in the Community of Madrid: A population-based cross-sectional study. Joint Bone Spine. 2023;90(4):105544.
Xuan Y, Zhang X, Wu H. Impact of sex differences on the clinical presentation, pathogenesis, treatment and prognosis of Sjögren's syndrome. Immunology. 2024;171(4):513-24.
Bowman SJ. Primary Sjögren's syndrome. Lupus. 2018;27(1_suppl):32-5.
Mihai A, Caruntu C, Jurcut C, Blajut FC, Casian M, Opris-Belinski D, et al. The spectrum of extraglandular manifestations in primary sjögren’s syndrome. Journal of personalized medicine. 2023;13(6):961.
Ye W, Chen S, Huang X, Qin W, Zhang T, Zhu X, et al. Clinical features and risk factors of neurological involvement in Sjögren’s syndrome. BMC neuroscience. 2018;19:1-8.
Fahad S, Khan A, Thapa P, Khan MS, Jogiyat S, Moustafa W, et al. Spectrum of Neurological Complications in Sjögren’s Syndrome: A Comprehensive Review. Cureus. 2025;17(3).
Salehi M, Zamiri A, Kim J, Texeira C, Shah K, Gunturu S. Exploring the psychiatric manifestations of primary Sjögren’s syndrome: A narrative review. International Journal of Rheumatology. 2024;2024(1):5520927.
Ging K, Mono M-L, Sturzenegger M, Zbinden M, Adler S, Genitsch V, et al. Peripheral and central nervous system involvement in a patient with primary Sjögren’s syndrome: a case report. Journal of medical case reports. 2019;13(1):1-7.
Fan G, Dai F, Chen S, Sun Y, Qian H, Yang G, et al. Neurological involvement in patients with primary Sjögren’s syndrome. JCR: Journal of Clinical Rheumatology. 2021;27(2):50-5.
Mekinian A, Tennenbaum J, Lahuna C, Dellal A, Belfeki N, Capron J, et al. Primary Sjögren’s syndrome: central and peripheral nervous system involvements. Clin Exp Rheumatol. 2020;38(Suppl 126):S103-9.
Cafaro G, Perricone C, Carubbi F, Baldini C, Quartuccio L, Priori R, et al. Peripheral nervous system involvement in Sjögren’s syndrome: analysis of a cohort from the Italian research group on Sjögren’s syndrome. Frontiers in Immunology. 2021;12:615656.
Fan W, Par-Young J, Li K, Zhang Y, Xiao P, Hua L, et al. Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome. Clinical Rheumatology. 2023;42(2):443-51.
Davies K, Ng W-F. Autonomic nervous system dysfunction in primary Sjögren’s syndrome. Frontiers in Immunology. 2021;12:702505.
Xuan J, Ji Z, Wang B, Zeng X, Chen R, He Y, et al. Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sjögren’s Syndrome. Frontiers in immunology. 2020;11:2826.
Mahgoub N. Primary Sjögren syndrome clinical and prognostic correlation. 2020.
Wei W, Ahmad SS, Chi S, Xie Y, Kamal MA, Li J. From molecular mechanism to the etiology of sjogren syndrome. Current pharmaceutical design. 2018;24(35):4177-85.
Roszkowska AM, Oliverio GW, Aragona E, Inferrera L, Severo AA, Alessandrello F, et al. Ophthalmologic manifestations of primary Sjögren’s syndrome. Genes. 2021;12(3):365.
Zhan Q, Zhang J, Lin Y, Chen W, Fan X, Zhang D. Pathogenesis and treatment of Sjogren’s syndrome: Review and update. Frontiers in immunology. 2023;14:1127417.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Annals of the rheumatic diseases. 2020;79(1):3-18.
Felten R, Scher F, Sibilia J, Gottenberg J-E, Arnaud L. The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: a systematic review of trials. Autoimmunity reviews. 2019;18(6):576-82.
Konak HE, Gök K, Armağan B, Güven SC, Atalar E, Apaydın H, et al. Neurological Involvement in Patients with Primary Sjögren’s Syndrome: A Retrospective Cross-Sectional Study. Annals of Indian Academy of Neurology. 2023;26(4):424-30.
Cafaro G, Perricone C, Carubbi F, Baldini C, Quartuccio L, Priori R, et al. Peripheral Nervous System Involvement in Sjögren’s Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren’s Syndrome. Frontiers in Immunology. 2021;12:898.
Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjögren syndrome. Nature reviews Disease primers. 2016;2(1):1-20.
Argyropoulou OD, Tzioufas AG. Common and rare forms of vasculitis associated with Sjögren's syndrome. Current opinion in rheumatology. 2020;32(1):21-8.
Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, et al. Sjögren’s syndrome: a systemic autoimmune disease. Clinical and experimental medicine. 2022;22(1):9-25.
Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis Rheumatol. 2021;73(6):1073-85.
Papadopoulos VE, Skarlis C, Evangelopoulos M-E, Mavragani CP. Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Review of Clinical Immunology. 2021;17(8):883-903.
Mondelo-Macía P, Castro-Santos P, Castillo-García A, Muinelo-Romay L, Diaz-Peña R. Circulating free DNA and its emerging role in autoimmune diseases. Journal of personalized medicine. 2021;11(2):151.
De Vita S, Gandolfo S. Predicting lymphoma development in patients with Sjögren’s syndrome. Expert review of clinical immunology. 2019;15(9):929-38.
Mariette X, Criswell LA. Primary Sjögren’s syndrome. New England Journal of Medicine. 2018;378(10):931-9.
Jacob A, He J, Peck A, Jamil A, Bunya V, Alexander JJ, et al. Metabolic changes during evolution of Sjögren's in both an animal model and human patients. Heliyon. 2025;11(1).
Alunno A, Carubbi F, Bartoloni E, Cipriani P, Giacomelli R, Gerli R. The kaleidoscope of neurological manifestations in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2019;37(Suppl 118):S192-8.
McCoy SS, Baer AN. Neurological Complications of Sjögren’s Syndrome: Diagnosis and Management. Current Treatment Options in Rheumatology. 2017;3(4):275-88.
Imgenberg-Kreuz J, Rasmussen A, Sivils K, Nordmark G. Genetics and epigenetics in primary Sjögren’s syndrome. Rheumatology. 2021;60(5):2085-98.
Margaretten M. Neurologic manifestations of primary Sjögren syndrome. Rheumatic Disease Clinics. 2017;43(4):519-29.
Borensztejn I, Ansari H, Siami-Namini K, Newman KA. Sjögren's Syndrome: an undiagnosed etiology for facial pain Case series with review of neurological manifestation of Sjögren syndrome. Autoimmun Rev. 2021;20(3):102762.
Seeliger T, Gehlhaar MA, Oluwatoba-Popoola I, Konen FF, Haar M, Donicova E, et al. Trigeminal nerve affection in patients with neuro-Sjögren detected by corneal confocal microscopy. J Clin Med. 2022;11(15):4484.
Pereira PR, Viala K, Maisonobe T, Haroche J, Mathian A, Hié M, et al. Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine. 2016;95(19).
Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society. European journal of neurology. 2010;17(7):903-e49.
Khandelwal D, Bhattacharya S, Khadgawat R, Kaur S, Tandon N, Ammini AC. Hypokalemic paralysis as a presenting manifestation of primary Sjögren's syndrome: A report of two cases. Indian J Endocrinol Metab. 2012;16(5):853-5.
Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup NB, Jensen TS. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol. 2017;16(11):934-44.
Indart S, Hugon J, Guillausseau PJ, Gilbert A, Dumurgier J, Paquet C, et al. Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review. Medicine (Baltimore). 2017;96(16):e6384.
Seeliger T, Prenzler NK, Gingele S, Seeliger B, Körner S, Thiele T, et al. Neuro-Sjögren: peripheral neuropathy With limb weakness in Sjögren's syndrome. Frontiers in immunology. 2019;10:1600.
Birnbaum J, Lalji A, Saed A, Baer AN. Biopsy‐proven small‐fiber neuropathy in primary Sjögren's syndrome: neuropathic pain characteristics, autoantibody findings, and histopathologic features. Arthritis care & research. 2019;71(7):936-48.
Zheng J, Zhang J, Jin Y, Wang Y, Xu L, Zheng H, et al. Characteristics of primary Sjögren’s syndrome-associated peripheral nervous system lesions. Journal of neurology. 2023;270(11):5527-35.
Zheng J, Zhang J, Xu L, Li Z, Ye H, Yang M, et al. Role of macrophages in peripheral nervous system involvement in patient with primary Sjogren’s syndrome. 2023.
Wu Z, Wang D, Chen L, Xianyu K, Yang H. Analysis of clinical features and risk factors of peripheral neuropathy in patients with primary Sjögren's syndrome. European Journal of Medical Research. 2023;28(1):54.
Perzyńska-Mazan J, Maślińska M, Gasik R. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018;56(2):99.
Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, Borrelli M, et al. Central nervous system involvement in Sjögren’s syndrome: unusual, but not unremarkable—clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology. 2010;49(8):1540-9.
Akasbi M, Berenguer J, Saiz A, Brito-Zerón P, Pérez-De-Lis M, Bové A, et al. White matter abnormalities in primary Sjögren syndrome. QJM: An International Journal of Medicine. 2012;105(5):433-43.
Cikes N. Central nervous system involvement in systemic connective tissue diseases. Clinical neurology and neurosurgery. 2006;108(3):311-7.
Alexander GE, Provost TT, Stevens MB, Alexander EL. Sjögren syndrome: central nervous system manifestations. Neurology. 1981;31(11):1391-.
den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology. 2005;64(2):263-7.
Ovbiagele B, Saver JL. Cerebral white matter hyperintensities on MRI: current concepts and therapeutic implications. Cerebrovascular Diseases. 2006;22(2-3):83-90.
Akasbi M, Berenguer J, Saiz A, Brito-Zerón P, Pérez-De-Lis M, Bové A, et al. White matter abnormalities in primary Sjögren syndrome. Qjm. 2012;105(5):433-43.
Teixeira F, Moreira I, Silva AM, Vasconcelos C, Farinha F, Santos E. Neurological involvement in Primary Sjögren Syndrome. Acta Reumatol Port. 2013;38(1):29-36.
Módis LV, Aradi Z, Horváth IF, Bencze J, Papp T, Emri M, et al. Central nervous system involvement in primary Sjögren’s syndrome: narrative review of MRI findings. Diagnostics. 2022;13(1):14.
Niu B, Zou Z, Shen Y, Cao B. A case report of Sjögren syndrome manifesting bilateral basal ganglia lesions. Medicine. 2017;96(17).
Le Guern V, Belin C, Henegar C, Moroni C, Maillet D, Lacau C, et al. Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjögren syndrome: a case–control study. Annals of the Rheumatic Diseases. 2010;69(01):132-7.
Delalande S, De Seze J, Fauchais A-L, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine. 2004;83(5):280-91.
Mataró M, Escudero D, Ariza M, Sánchez-Ojanguren J, Latorre P, Junqué C, et al. Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sjögren syndrome. Journal of neurology. 2003;250(9):1070-6.
Saied Z, Zouari R, Rachdi A, Nabli F, Mohamed DB, Sassi SB. Cerebral large vessels vasculitis following Guillain-Barré syndrome as first clinical manifestations of primary Sjogren’s syndrome: a case based–review. Heliyon. 2024.
De Oliveira FR, Fantucci MZ, Adriano L, Valim V, Cunha TM, Louzada-Junior P, et al. Neurological and inflammatory manifestations in Sjögren’s syndrome: The role of the kynurenine metabolic pathway. International journal of molecular sciences. 2018;19(12):3953.
Verma R, Lalla R, Patil TB, Mehta V. Acute myeloneuropathy: An uncommon presentation of Sjögren's syndrome. Annals of Indian Academy of Neurology. 2013;16(4):696.
Jamilloux Y, Magy L, Hurtevent J-F, Gondran G, de Seze J, Launay D, et al. Immunological profiles determine neurological involvement in Sjögren's syndrome. European Journal of Internal Medicine. 2014;25(2):177-81.
Perzyńska-Mazan J, Maślińska M, Gasik R. Neurophysiological features of peripheral nervous system involvement and immunological profile of patients with primary Sjögren syndrome. The Journal of rheumatology. 2020;47(11):1661-7.
England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, et al. Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve. 2009;39(1):106-15.
Tobón GJ, Pers JO, Devauchelle-Pensec V, Youinou P. Neurological Disorders in Primary Sjögren's Syndrome. Autoimmune Dis. 2012;2012:645967.
Grant IA, Hunder GG, Homburger HA, Dyck PJ. Peripheral neuropathy associated with sicca complex. Neurology. 1997;48(4):855-62.
Maślińska M, Wojciechowska B, Mańczak M, Kwiatkowska B. Serum immunoglobulin G4 in Sjögren’s syndrome: a pilot study. Rheumatology International. 2020;40(4):555-61.
Camdessanché JP, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain. 2009;132(Pt 7):1723-33.
Malinow K, Yannakakis G, Glusman S, Edlow D, Griffin J, Pestronk A, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1986;20(4):535-7.
Zong Y, Yang Y, Zhao J, Li L, Luo D, Hu J, et al. Characterisation of macrophage infiltration and polarisation based on integrated transcriptomic and histological analyses in Primary Sjögren’s syndrome. Frontiers in immunology. 2023;14:1292146.
Qi W, Tian J, Wang G, Yan Y, Wang T, Wei Y, et al. Advances in cellular and molecular pathways of salivary gland damage in Sjögren’s syndrome. Frontiers in Immunology. 2024;15:1405126.
Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol. 1990;27(3):304-15.
Yadav R, Krishnan P, Kulkarni GB, Yasha T, Kumar MV, Nagraja D. Spectrum of Neuro-Sjogren's syndrome in a tertiary care center in south India. Annals of Indian Academy of Neurology. 2011;14(2):111.
Quartuccio L, Baldini C, Priori R, Bartoloni E, Carubbi F, Alunno A, et al. Cryoglobulinemia in Sjögren syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue. The Journal of rheumatology. 2017;44(8):1179-83.
Tuominen IS, Konttinen YT, Vesaluoma MH, Moilanen JA, Helintö M, Tervo TM. Corneal innervation and morphology in primary Sjögren's syndrome. Invest Ophthalmol Vis Sci. 2003;44(6):2545-9.
Barcelos F, Hipólito‐Fernandes D, Martins C, Ângelo‐Dias M, Cardigos J, Monteiro R, et al. Corneal sub‐basal nerve plexus assessment and its association with phenotypic features and lymphocyte subsets in Sjögren's Syndrome. Acta Ophthalmologica. 2021.
Pavlakis P, Alexopoulos H, Kosmidis M, Mamali I, Moutsopoulos H, Tzioufas A, et al. Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. Journal of autoimmunity. 2012;39(1-2):27-33.
Rassi DM, De Paiva CS, Dias LC, Módulo CM, Adriano L, Fantucci MZ, et al. MicroRNAS in ocular surface and dry eye diseases. The ocular surface. 2017;15(4):660-9.
Owada K, Uchihara T, Ishida K, Mizusawa H, Watabiki S, Tsuchiya K. Motor weakness and cerebellar ataxia in Sjögren syndrome—identification of antineuronal antibody: a case report. Journal of the neurological sciences. 2002;197(1-2):79-84.
Konsta OD, Thabet Y, Le Dantec C, Brooks WH, Tzioufas AG, Pers J-O, et al. The contribution of epigenetics in Sjögren’s Syndrome. Frontiers in genetics. 2014;5:71.
Qiao L, Wang Q, Fei Y, Zhang W, Xu Y, Zhang Y, et al. The clinical characteristics of primary Sjogren's syndrome with neuromyelitis optica spectrum disorder in China: a STROBE-compliant article. Medicine. 2015;94(28).
Jamilloux Y, Magy L, Hurtevent JF, Gondran G, de Seze J, Launay D, et al. Immunological profiles determine neurological involvement in Sjögren's syndrome. Eur J Intern Med. 2014;25(2):177-81.
Alexander EL. Neurologic disease in Sjogren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle: a clinical review and update of immunopathogenesis. Rheumatic disease clinics of North America. 1993;19(4):869-908.
Peyronnard JM, Charron L, Beaudet F, Couture F. Vasculitic neuropathy in rheumatoid disease and Sjögren syndrome. Neurology. 1982;32(8):839-45.
Alexander EL, Ranzenbach MR, Kumar AJ, Kozachuk WE, Rosenbaum AE, Patronas N, et al. Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology. 1994;44(5):899-908.
Chiorini J, Cihakova D, Ouellette C, Caturegli P. Sjögren syndrome: advances in the pathogenesis from animal models. Journal of autoimmunity. 2009;33(3-4):190-6.
Alexander EL, Lijewski JE, Jerdan MS, Alexander GE. Evidence of an immunopathogenic basis for central nervous system disease in primary Sjögren's syndrome. Arthritis Rheum. 1986;29(10):1223-31.
Elnady B, Fathy SM, Elkhouly T, Ganeb S. Neuromyelitis optica spectrum standstill in rheumatic systemic autoimmune diseases. Egyptian Rheumatology and Rehabilitation. 2020;47(1):1-8.
de Seze J, Devos D, Castelnovo G, Labauge P, Dubucquoi S, Stojkovic T, et al. The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology. 2001;57(8):1359-63.
Park J-H, Hwang J, Min J-H, Kim BJ, Kang E-S, Lee KH. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. Journal of the neurological sciences. 2015;348(1-2):132-5.
Li J-A, Meng H-M, Cui Z-T, Wang X, Miao J. Recurrent cerebral infarctions in primary Sjögren syndrome: A case report and literature review. Frontiers in neurology. 2018;9:865.
Collison K, Rees J. Asymmetric cerebellar ataxia and limbic encephalitis as a presenting feature of primary Sjögren's syndrome. Journal of Neurology. 2007;254(11):1609-11.
Çoban A, Özyurt S, Meriç K, Mısırlı H, Tüzün E, Türkoğlu R. Limbic encephalitis associated with Sjögren's syndrome: report of three cases. Internal Medicine. 2016;55(16):2285-9.
Shimizu F, Nishihara H, Kanda T. Blood–brain barrier dysfunction in immuno-mediated neurological diseases. Immunological medicine. 2018;41(3):120-8.
Jonsson R, Brokstad KA, Jonsson MV, Delaleu N, Skarstein K. Current concepts on Sjögren's syndrome–classification criteria and biomarkers. European journal of oral sciences. 2018;126:37-48.
Tetsuka S, Suzuki T, Ogawa T, Hashimoto R, Kato H. Anti-Ro/SAA Autoantibodies Might Represent the Antineuronal Antibodies Responsible for Cerebellar Degeneration in Sjögren's Syndrome. J Clin Med Res. 2021;13(2):113-20.
Estiasari R, Matsushita T, Masaki K, Akiyama T, Yonekawa T, Isobe N, et al. Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjogren's syndrome patients with central nervous system manifestations. Mult Scler. 2012;18(6):807-16.
Lauvsnes MB, Beyer MK, Kvaløy JT, Greve OJ, Appenzeller S, Kvivik I, et al. Association of hippocampal atrophy with cerebrospinal fluid antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor in patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome. Arthritis Rheumatol. 2014;66(12):3387-94.
Lauvsnes MB, Maroni SS, Appenzeller S, Beyer MK, Greve OJ, Kvaløy JT, et al. Memory dysfunction in primary Sjögren's syndrome is associated with anti-NR2 antibodies. Arthritis Rheum. 2013;65(12):3209-17.
Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129(Pt 7):1659-73.
Bårdsen K, Brede C, Kvivik I, Kvaløy JT, Jonsdottir K, Tjensvoll AB, et al. Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjögren’s syndrome. Journal of neuroinflammation. 2019;16(1):1-9.
Rogóz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002;42(8):1024-30.
Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. Journal of neural transmission. 2014;121(8):1029-75.
Lauvsnes M, Tjensvoll A, Maroni S, Kvivik I, Grimstad T, Greve O, et al. The blood–brain barrier, TWEAK, and neuropsychiatric involvement in human systemic lupus erythematosus and primary Sjögren’s syndrome. Lupus. 2018;27(13):2101-11.
Yao Y, Ma J-F, Chang C, Xu T, Gao C-Y, Gershwin ME, et al. Immunobiology of T Cells in Sjögren’s Syndrome. Clinical Reviews in Allergy & Immunology. 2021;60(1):111-31.
Roescher N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome. Oral diseases. 2009;15(8):519-26.
Ter Borg EJ, Kelder JC. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren's syndrome : A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort. Rheumatol Int. 2017;37(7):1153-8.
Li H, Reksten TR, Ice JA, Kelly JA, Adrianto I, Rasmussen A, et al. Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS genetics. 2017;13(6):e1006820.
Rahat B, Ali T, Sapehia D, Mahajan A, Kaur J. Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine. Front Genet. 2020;11:844.
Bartoloni E, Ludovini V, Alunno A, Pistola L, Bistoni O, Crinò L, et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren's syndrome. Lupus. 2011;20(9):928-35.
Beck J, Urnovitz HB, Saresella M, Caputo D, Clerici M, Mitchell WM, et al. Serum DNA motifs predict disease and clinical status in multiple sclerosis. The Journal of Molecular Diagnostics. 2010;12(3):312-9.
Dunaeva M, Derksen M, Pruijn GJM. LINE-1 Hypermethylation in Serum Cell-Free DNA of Relapsing Remitting Multiple Sclerosis Patients. Mol Neurobiol. 2018;55(6):4681-8.
Lee DH, Lee SJ. Recurrent aseptic meningitis as an initial clinical presentation of primary Sjögren’s syndrome. Journal of Neurocritical Care. 2019;12(1):46-50.
Fauchais A-L, Magy L, Vidal E. Central and peripheral neurological complications of primary Sjögren's syndrome. La Presse Médicale. 2012;41(9):e485-e93.
Brunner M, Guggisberg D, Sprecher M, Pastva O, Bürki K, Houtman M, et al. Pro-Inflammatory Properties of Salivary Gland-Derived Fibroblasts—Implications in Sjögren’s Disease. Cells. 2025;14(8):558.
Griffin J, Cornblath D, Alexander E, Campbell J, Low P, Bird S, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990;27(3):304-15.
Inoue A, Koh CS, Tsukada N, Yanagisawa N. Peripheral neuropathy associated with Sjögren's syndrome: pathologic and immunologic study of two patients. Jpn J Med. 1991;30(5):452-7.
Alexander E, Ranzenbach M, Kumar A, Kozachuk W, Rosenbaum A, Patronas N, et al. Anti‐Ro (SS‐A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS‐SS): Clinical, neuroimaging, and angiographic correlates. Neurology. 1994;44(5):899-.
Tetsuka S, Suzuki T, Ogawa T, Hashimoto R, Kato H. Anti-Ro/SAA Autoantibodies Might Represent the Antineuronal Antibodies Responsible for Cerebellar Degeneration in Sjögren's Syndrome. 2020.
Afzali AM, Moog P, Kalluri SR, Hofauer B, Knopf A, Kirschke JS, et al. CNS demyelinating events in primary Sjögren's syndrome: A single-center case series on the clinical phenotype. Frontiers in neurology. 2023;14:1128315.
Yilmaz FC, Kisaoglu H, Baba O, Kalyoncu M. Spectrum of Central Nervous System Involvement in Childhood-Onset Sjögren’s Syndrome: A Case-Based Review. Mediterranean Journal of Rheumatology. 2024;35(2):298.
Bandler M, Bhugra M, Thiruvasahar T, Ranatunga S. Orbital Inflammatory Disease as Initial Presentation of Primary Sjögren Syndrome. Annals of Internal Medicine: Clinical Cases. 2024;3(4):e231093.
Mihai A, Chitimus DM, Jurcut C, Blajut FC, Opris-Belinski D, Caruntu C, et al. Comparative Analysis of Hematological and Immunological Parameters in Patients with Primary Sjögren’s Syndrome and Peripheral Neuropathy. J Clin Med. 2023;12(11):3672.
Ramos-Casals M, Brito-Zerón P. Emerging biological therapies in primary Sjögren's syndrome. Rheumatology. 2007;46(9):1389-96.
Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain. 2005;128(11):2518-34.
Asahina M, Kuwabara S, Nakajima M, Hattori T. D-penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjögren's syndrome. Neurology. 1998;51(5):1451-3.
Kastrup O, Maschke M, Diener H. Pulse-cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren's syndrome. Clinical neurology and neurosurgery. 2004;107(5):440-1.
Caselli RJ, Scheithauer BW, Bowles CA, Trenerry MR, Meyer FB, Smigielski JS, et al. The treatable dementia of Sjögren's syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1991;30(1):98-101.
Ozgocmen S, Gur A. Treatment of central nervous system involvement associated with primary Sjogren's syndrome. Current pharmaceutical design. 2008;14(13):1270-3.
Wang K-C, Wang S-J, Lee C-L, Chen S-Y, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. Journal of Clinical Neuroscience. 2011;18(1):43-6.
Terrier B, Lacroix C, Guillevin L, Hatron PY, Dhote R, Maillot F, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome–related neuropathy. Arthritis Care & Research. 2007;57(8):1520-9.
Nocturne G, Cornec D, Seror R, Mariette X. Use of Biologics in Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):407-17.
Caroyer J-M, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren’s syndrome. Neurology. 2002;59(7):1113-4.
Tobón GJ, Pers J-O, Devauchelle-Pensec V, Youinou P. Neurological disorders in primary Sjögren's syndrome. Autoimmune diseases. 2012;2012.
Hammett EK, Fernandez-Carbonell C, Crayne C, Boneparth A, Cron RQ, Radhakrishna SM. Adolescent Sjogren’s syndrome presenting as psychosis: a case series. Pediatric Rheumatology. 2020;18(1):1-8.
SHIOZAWA S, TANAKA Y, SHIOZAWA K. Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjögren's syndrome. Journal of interferon & cytokine research. 1998;18(4):255-62.
Zheng L, Zhang Z, Yu C, Tu L, Zhong L, Yang C. Association between IFN-α and primary Sjogren's syndrome. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2009;107(1):e12-e8.
Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome: potential therapeutic targets. Annals of the rheumatic diseases. 2010;69(6):945-8.
Yamada S, Mori K, Matsuo K, Inukai A, Kawagashira Y, Sobue G. Interferon alfa treatment for Sjögren’s syndrome associated neuropathy. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(4):576-8.
Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(8):967-9.
Morozumi S, Kawagashira Y, Iijima M, Koike H, Hattori N, Katsuno M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. Journal of the neurological sciences. 2009;279(1-2):57-61.
Goodman BP. Immunoresponsive autonomic neuropathy in sjögren syndrome—case series and literature review. American journal of therapeutics. 2019;26(1):e66-e71.
Rist S, Sellam J, Hachulla E, Sordet C, Puéchal X, Hatron Py, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: a national multicentric retrospective study. Arthritis care & research. 2011;63(9):1339-44.
Lokhandwala PM, Shabihkhani M, Ness PM, Bloch EM. Therapeutic plasma exchange for hyperviscosity syndrome secondary to high rheumatoid factor. Transfusion and Apheresis Science. 2018;57(2):225-7.
Kang H, Jung Y-h, Moon J, Ryu JS, Yoon CH, Kim YH, et al. Efficacy of RCI001 as a Therapeutic Candidate in a Primary Sjögren Syndrome Mouse Model. Cornea. 2025;44(2):226-33.
Harrell CR, Volarevic A, Arsenijevic A, Djonov V, Volarevic V. Targeted Therapy for Severe Sjogren’s Syndrome: A Focus on Mesenchymal Stem Cells. Int J Mol Sci. 2024;25(24):13712.
Zou Y, Xiao W, Liu D, Li X, Li L, Peng L, et al. Human umbilical cord mesenchymal stem cells improve disease characterization of Sjogren's syndrome in NOD mice through regulation of gut microbiota and Treg/Th17 cellular immunity. Immunity, inflammation and disease. 2024;12(1):e1139.
Li B, Xing Y, Gan Y, He J, Hua H. Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sjögren's syndrome by modulating the balance of Treg and Th17 cells. Stem cell research & therapy. 2021;12(1):478.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
